Long Island Chapter
www.lls.org/li
News
The Leukemia & Lymphoma Society and Dana-Farber Cancer Institute to Bring Clinical Trials to Local Communities
Partnership Seeks to Accelerate Development of Innovative Therapies
LLS Applauds FDA's Approval of Lenalidomide for Patients with Relapsed or Refractory Mantle Cell Lymphoma
Approval marks first oral therapy for MCL patients, and a new option for patients with unmet medical need
The Leukemia & Lymphoma Society and Valor Biotherapeutics Partner to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
Anti-CD20-Interferon Alpha Fusion Protein is a promising therapy for NHL patients resistant to standard therapy
News
Media Contacts
If you're a member of the media, you can direct all inquiries for The Leukemia & Lymphoma Society's (LLS's) Long Island Chapter's email theleukemialymphomasociety_NYL@lls.org or call 631-370-7530.
last updated on
Monday, April 11, 2011
